Fludroxycortide cream as an alternative therapy for actinic cheilitis
Abstract
Objectives
The
objective of the study is to assess, by clinical follow-up, the
efficacy of the dermatological cream Fludroxycortide 0.125 mg/g
(Drenison®) in the treatment of actinic cheilitis (AC).
Material and methods
Twenty-three
patients diagnosed with AC participated in the study. Fifteen were
submitted to corticotherapy with Fludroxycortide, applied three times a
day for up to 6 weeks, associated with lip sunscreen (LS) before sun
exposure. In the control group of eight patients, only the use of LS was
established. At each weekly return, a photographic record was made of
the lesion. After treatment, images were evaluated and scores were
assigned to verify clinical evolution. Also, patients treated with
Fludroxycortide responded to a questionnaire, to assess drug
tolerability and treatment satisfaction.
Results
In the group treated with Fludroxycortide (n = 15),
five patients showed total improvement, seven presented partial
improvement, and three showed no clinical change. Concerning the
patients treated with LS (n = 8),
one presented total remission of the clinical lesion characteristics,
four exhibited partial improvement, and three exhibited no clinical lip
alteration. No case presented symptom worsening. Of the 15 patients
undergoing corticotherapy, 12 were satisfied and reported that the
product was not irritating and contributed to lesion improvement.
Conclusions
Conventional
treatment with LS was effective in the remission of some AC lesions,
but treatment responses were improved when associated with
Fludroxycortide, especially in the more severe cases.
Clinical relevance
As
it is a non-invasive therapy leading, in most cases, to adequate
clinical results, safety, and tolerability, Fludroxycortide can be
considered an effective alternative treatment for AC.
Comments